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Abstract
Background: Xpert MTB/RIF (Xpert) is a promising new rapid diagnostic technology for tuberculosis (TB) that has
characteristics that suggest large-scale roll-out. However, because the test is expensive, there are concerns among TB
program managers and policy makers regarding its affordability for low- and middle-income settings.
Methods and Findings: We estimate the impact of the introduction of Xpert on the costs and cost-effectiveness of TB care
using decision analytic modelling, comparing the introduction of Xpert to a base case of smear microscopy and clinical
diagnosis in India, South Africa, and Uganda. The introduction of Xpert increases TB case finding in all three settings; from
72%–85% to 95%–99% of the cohort of individuals with suspected TB, compared to the base case. Diagnostic costs
(including the costs of testing all individuals with suspected TB) also increase: from US$28–US$49 to US$133–US$146 and
US$137–US$151 per TB case detected when Xpert is used ‘‘in addition to’’ and ‘‘as a replacement of’’ smear microscopy,
respectively. The incremental cost effectiveness ratios (ICERs) for using Xpert ‘‘in addition to’’ smear microscopy, compared
to the base case, range from US$41–$110 per disability adjusted life year (DALY) averted. Likewise the ICERS for using Xpert
‘‘as a replacement of’’ smear microscopy range from US$52–$138 per DALY averted. These ICERs are below the World Health
Organization (WHO) willingness to pay threshold.
Conclusions: Our results suggest that Xpert is a cost-effective method of TB diagnosis, compared to a base case of smear
microscopy and clinical diagnosis of smear-negative TB in low- and middle-income settings where, with its ability to
substantially increase case finding, it has important potential for improving TB diagnosis and control. The extent of cost-
effectiveness gain to TB programmes from deploying Xpert is primarily dependent on current TB diagnostic practices.
Further work is required during scale-up to validate these findings.
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Introduction
Tuberculosis (TB) control in developing countries is hampered
by the inadequate care that can be delivered on the basis of
diagnosis by microscopy alone—an issue that is acute in
populations with a high prevalence of HIV and/or multidrug
resistant (MDR)-TB. It is estimated that 1.7 million people died
from TB in 2009, many of them remaining undiagnosed [1]. The
Xpert MTB/RIF assay (referred to as Xpert in this article), is a
real-time PCR assay that is a design-locked, all-within-cartridge
test, and that has demonstrated high performance and could be
deployed in a range of low- and middle-income settings [2,3]. It
has recently been endorsed by the World Health Organization
(WHO) as a promising new rapid diagnostic technology that has
the potential for large-scale roll-out (www.who.int/tb/laboratory).
Xpert is commercially produced and sold at concessional prices.
However, because the price is considerably higher than that of
smear microscopy, there is a concern among TB program
managers and policy makers that Xpert may not be cost-effective
in low- and middle-income settings.
There is little previous research into the cost-effectiveness of TB
diagnostics. A study considering a hypothetical TB diagnostic
found that cost-effectiveness would be maximized by high-
specificity, low-cost tests deployed in regions with poor infrastruc-
ture [4]. Other studies have examined the cost-effectiveness of
culture, PCR, and novel methods for drug susceptibility testing
such as line-probe assays (LPA). These studies all found that these
diagnostic tests are potentially cost-effective [5–7]. However,
because of their technical requirements, mycobacterial culture,
PCR, and LPA can only be deployed in specialised laboratories.
We present the first (to our knowledge) economic evaluation of the
Xpert rapid test for TB. [2].
Methods
The aim of this study was to assess whether Xpert is likely to
result in an improvement of the cost-effectiveness of TB care in
low- and middle-income settings. We did this by estimating the
impact of Xpert on the costs and cost-effectiveness of TB care in
three countries, using decision analytic modelling, comparing the
introduction of Xpert to a base case of sputum microscopy and
clinical diagnosis. The model’s primary outcome measure is the
cost per disability adjusted life year (DALY) averted.
Our model followed a cohort of 10,000 individuals suspected
of having TB through the diagnostic and treatment pathway,
estimating costs and health gains. In the diagnostic pathway, the
TB cases among the individuals with suspected TB were either
diagnosed as having TB or not, depending on the test sensitivities
in the pathway. Similarly, individuals with suspected TB who were
not TB cases may have been diagnosed as having TB, depending
on the pathway’s test specificities. A diagnosis of TB was followed
by treatment. Individuals with suspected TB completed the
pathway when they were either cured, failed treatment, died, or,
if they had no TB from the start, remained without TB.
Three different diagnostic scenarios are compared (Figure 1).
The base case is defined as two sputum microscopy examinations
followed, in smear-negative individuals with suspected TB, by
clinical diagnosis that might include chest X-ray and antibiotic
trial [8]. The inclusion of an antibiotic trial (empirical treatment
with one or more broad-spectrum antibiotics to exclude other
infectious causes of pulmonary disease) is no longer part of the
WHO diagnostic strategy for HIV-infected patients. However, in
the clinics participating in the demonstration study from which the
diagnostic performance parameters were sourced [2], an antibiotic
trial was still commonly provided during the diagnostic process as
an adjunct to the treatment of smear-negative individuals with
suspected TB. Antibiotic trial was therefore included in the base
case; the model assumed that for each country the use of antibiotic
trial and chest X-ray was proportional to the observed use in the
demonstration study clinics. In comparison, two alternative
pathways involving Xpert were considered: (1) two smear
examinations, if negative followed by Xpert on a single sputum
specimen (‘‘in addition to’’); (2) Xpert instead of smear
examination: single sputum specimen tested by Xpert for all
individuals with suspected TB (‘‘replacement of’’).
Each scenario included drug resistance testing of previously
treated patients [9], either by conventional drug susceptibility
testing (DST) or Xpert. All patients diagnosed with TB were
treated using the standard WHO-recommended regimens.
Patients awaiting DST results were started on first-line treatment
(isoniazid [H], rifampicin [R], pyrazimamide [Z], and ethambutol
[E] for 2 mo followed by HR for 4 mo for new patients, and
HRZE for 3 mo with streptomycin added during the first 2 mo
followed by HRE for 5 mo for patients with a history of previous
TB treatment) and switched to second-line treatment when a DST
result of rifampicin resistance became available. The second-line
treatment regimens differed between the countries but commonly
included a fluoroquinolone and an aminoglycoside (kanamycin,
amikacin) or capreomycin in addition to one or more first-line
drugs and ethionamode, cycloserine, and/or 4-aminosalicylic acid
(PAS). If Xpert identified rifampicin resistance, this was con-
firmed by conventional DST or LPA as practice in the respective
countries. LPA, used as a screening test on smear-positive sputum
samples in South Africa, detects rifampicin resistance within 24 h
by molecular methods. While awaiting this result, the patient was
started on second-line treatment, but then switched to first-line
treatment if resistance to rifampicin was not confirmed. TB cases
that remained undiagnosed were assumed to return to the clinic
after 3 mo, with 10% of undiagnosed cases becoming smear-
positive within that time.
Key model input parameters are shown in Table 1 and further
details can be found in Text S1. The model was parameterised for
three settings: India (low HIV prevalence, low MDR prevalence),
Uganda (high HIV prevalence, low MDR prevalence), and South
Africa (high HIV prevalence, high MDR prevalence). In each
cohort, TB cases were characterized as: (1) new or previously
treated, (2) HIV-negative or HIV-positive, and (3) MDR or drug
susceptible. These proportions were sourced from country reports
[1,10,11].
Diagnostic test performance data were sourced from a
demonstration study of Xpert use in nine facilities [2]. Sensitivity
and specificity parameters for all diagnostic tests and procedures
were calculated taking sputum culture as the reference standard.
The sensitivity and specificity of Xpert and sputum microscopy
(light-emitting diode [LED]) fluorescence microscopy) was based
on weighted averages across the sites. Since clinical diagnostic
practice of smear negatives in the base case varied considerably
between sites, site-specific data were used to estimate perfor-
mance of the clinical TB diagnosis. A patient was defined as
having clinically diagnosed TB if microscopy was negative, but
the onset of treatment preceded the availability of the culture
result.
Estimates of the economic costs of each pathway were made
from a health service perspective. All costs were estimated using
the ingredient costing approach. This approach identifies all the
inputs (and their quantities) required to perform a test or deliver
treatment and then values them to arrive at a cost per test/person
treated.
Cost-Effectiveness of Xpert MTB/RIF
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Diagnostic costs were collected at the demonstration sites. These
costs included all building, overhead, staff, equipment and
consumables, quality control and maintenance, and calibration
inputs. The resource use associated with each test was measured
through observations of practice, a review of financial report-
ing, and interviews with staff in the Xpert demonstration sites.
Resource use measurement took into account the allocation of
fixed resources between Xpert and any other uses. Estimates of
device and test prices, calibration, and training costs were obtained
from suppliers. Costs for treatment were estimated using drugs
costs from the Global Drug Facility and the MSH International
Price Tracker, and unit costs for outpatient visits and hospitalisa-
tion sourced from WHO-CHOICE [12]. A review of previous
costing studies was used to validate these estimates [13–18]. As our
constructed estimates were higher than those found in our review,
we took the mid-point between our estimate and the lowest estimate
found in the literature. All local costs were converted using the
average exchange rate for 2010 (imf.statex.imf.org). Where relevant,
costs were annualised using a standard discount rate of 3% [19]. All
costs are reported in 2010 US$. Treatment outcome probabilities
were taken from published meta-analyses of clinical trials, cohort
studies, and systematic reviews [20–28]. DALYs averted from
patients being cured were estimated using the standard formula
[19]. Further details can be found in Text S1.
Since the Xpert scenarios are most likely to be more costly and
more effective than the base case, an incremental cost effectiveness
ratio (ICER) was calculated to describe the additional cost for any
additional DALYs averted by Xpert over the base case. This
ICER was then compared to WHO’s suggested country-specific
willingness to pay (WTP) threshold, defined as the cost per DALY
averted of each country’s per capita GDP (US$1,134 for India,
US$5,786 for South Africa, and US$490 for Uganda in 2010). If
the ICER is below this threshold the intervention is considered
cost-effective.
Figure 1. Simplified schematic of model.
doi:10.1371/journal.pmed.1001120.g001
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Table 1. Model inputs: cohort composition and diagnostic parameters, by country.
Cohort Proportions and Diagnostic Parameters India South Africa Uganda Distribution Source
Cohort proportions
Smear-positive TB 0.1 0.1 0.1 Beta Model assumption
Smear-positive TB among pulmonary TB cases, HIV-negative 0.723 0.723 0.723 Beta Demonstration study, all sites [2]
Smear-positive TB among pulmonary TB cases, HIV-positive 0.446 0.446 0.446 Beta Demonstration study, all sites [2]
Previous TB treatment among pulmonary TB cases 0.192 0.168 0.073 Beta WHO [1]
Multidrug resistance, among new TB cases 0.023 0.066 0.011 Beta WHO [10]
Multidrug resistance, among previously treated TB cases 0.172 0.245 0.117 Beta WHO [10], survey [11]
HIV infection, among pulmonary TB cases 0.006 0.588 0.593 Beta WHO [1]
Diagnostic parameters
Sensitivity for diagnosing pulmonary TB (SEM)
Xpert MTB RIF, smear-positive TB cases 0.983 (0.005) 0.983 (0.005) 0.983 (0.005) Beta Demonstration study, all sites [2]
Xpert MTB RIF, smear-negative TB cases, HIV-negative 0.793 (0.025) 0.793 (0.025) 0.793 (0.025) Beta Demonstration study, all sites [2]
Xpert MTB RIF, smear-negative cases, HIV-positive 0.718 (0.040) 0.718 (0.040) 0.718 (0.040) Beta Demonstration study, all sites [2]
Smear microscopy (two slides), HIV-positive 0.723 (0.015) 0.723 (0.015) 0.723 (0.015) Beta Demonstration study, all sites [2]
Smear microscopy (two slides), HIV-negative 0.446 (0.036) 0.446 (0.036) 0.446 (0.036) Beta Demonstration study, all sites [2]
Mycobacterial culture 1 (—) 1 (—) 1 (—) Model assumption
Clinical diagnosis 0.160 (0.073) 0.209 (0.039) 0.444 (0.096) Beta Demonstration study [2]
Proportion culture-positive individuals with suspected TB
who had chest X-ray
0.032 0.262 0.867 Beta Demonstration study [2]
Proportion culture-positive individuals with suspected TB
who had antibiotic trial
1 0.051 0.241 Beta Demonstration study [2]
Specificity for diagnosing pulmonary TB (SEM)
Xpert MTB RIF 0.990 (0.002) 0.990 (0.002) 0.990 (0.002) Beta Demonstration study, all sites [2]
Smear microscopy (two slides) 1 (—) 1 (—) 1 (—) Model assumption
Mycobacterial culture 1 (—) 1 (—) 1 (—) Model assumption
Clinical diagnosis 0.942 (0.009) 0.953 (0.007) 0.869 (0.030) Beta Demonstration study [2]
Proportion culture-negative individuals with suspected TB
who had chest X-ray
0.037 0.059 0.790 Beta Demonstration study [2]
Proportion culture-negative individuals with suspected TB
who had antibiotic trial
1 0.009 0.887 Beta Demonstration study [2]
Sensitivity for detecting rifampicin-resistance (SEM)
Xpert MTB RIF 0.944 (0.015) 0.944 (0.015) 0.944 (0.015) Beta Demonstration study, all sites [2]
Conventional drug susceptibility testing 1 (—) — 1 (—) — Model assumption
Line-probe assay — 1 (—) — — Model assumption
Specificity for detecting rifampicin-resistance (SEM)
Xpert MTB RIF 0.983 (0.005) 0.983 (0.005) 0.983 (0.005) Beta Demonstration study, all sites [2]
Drug susceptibility testing 1 (—) — 1 (—) — Model assumption
Line-probe assay — 1 (—) — — Model assumption
Cost parameters US$ 2010 (min, max)
First-line category 1 treatment: total 227 (103, 352) 454(306, 602) 185 (146, 224) Triangular WHO-CHOICE [13], literature review
[14–19]
First-line category 2 treatment: total 352 (159, 546) 998 (451, 1546) 287 (130, 445) Triangular WHO-CHOICE [13], literature review
[14–19]
Cotrimoxazol preventive treatment: 1 mo 4, 50 10, 53 3, 25 Triangular WHO-CHOICE [13]
Treatment of bacterial infection 3, 66 9, 70 2, 41 Triangular WHO-CHOICE [13]
Chest X-ray 11 (9, 13) 16 (14, 18) 3 (2.6, 3.7) Triangular WHO-CHOICE [13], literature review
[14–19]
Second-line treatment total 2,256 (1,463,
3,050)
3,492 (2,068,
4,917)
1,759 (1,285,
2,233)
Triangular WHO-CHOICE [13], literature review
[14–19]
DALY parameters: DALYs averted (min, max)
HIV positive, sputum smear-negative 9.38 (8.62,
10.39)
10.71 (9.85,
11.90)
11.58 (10.63,
12.90)
Triangular See Text S1
HIV negative, sputum smear-negative 13.18 (12.32,
13.96)
13.83 (12.83,
14.72)
18.65 (17.56,
19.61)
Triangular See Text S1
Cost-Effectiveness of Xpert MTB/RIF
PLoS Medicine | www.plosmedicine.org 4 November 2011 | Volume 8 | Issue 11 | e1001120
In the demonstration study from which our parameter estimates
were sourced [2], the probability that an individual with suspected
TB was a true TB case varied considerably by location; the
proportion with smear-positive TB being 8.9% in India, 14.3% in
South Africa, and 32.4% in Uganda. This variation probably
reflects the local patterns of (self-) referral, in particular for the
extremely high proportion of TB cases among the individuals with
suspected TB in Uganda. Therefore to enable generalizability, we
assumed a 10% proportion of smear-positive TB in individuals
with suspected TB for all three countries as our point estimate with
a range of 2.5% to 25% in our uncertainty and sensitivity analyses
[29].
A large number of one- and two-way sensitivity analyses were
conducted to assess the robustness of our model. These analyses
examine the robustness of our results when one or two parameters
are varied between the outer limits of their confidence intervals.
We examined the sensitivity of our results to the probability that a
suspect has TB or MDR-TB or has been previously treated. We
examined the impact of varying treatment costs on our results. We
tested for different prices of Xpert cartridge. We examined the
impact of varying the proportion of individuals with suspected TB
who get chest X-ray in addition to Xpert, as physicians may
continue clinical diagnosis for smear-negative TB. Similarly we
examined the impact of assuming that all HIV-infected individuals
with suspected TB who have negative Xpert undergo the clinical
diagnosis procedure, with costs based on site-specific use of chest
X-rays and antibiotics, and sensitivity and specificity based on
site-specific diagnostic performance of clinical diagnosis. We
assessed the sensitivity of our results to the performance of the
base case in three ways: (1) assuming one instead of two smears;
(2) by varying the sensitivity of smear examination; and (3) by
replacing the site-specific performance estimates for clinical
diagnosis with estimates averaged across the three sites. Recog-
nising that the performance of clinical diagnosis is a trade-off
between sensitivity and specificity, we varied the sensitivity and
specificity in opposite directions across a plausible range of values.
As physicians in the demonstration study were aware that they
would receive the results of sputum culture of all individuals with
suspected TB, we tested for the effect of deferring treatment
decisions until the availability of culture results. For each site
culture was costed and assessed on the basis of current practice.
We did not include a sensitivity analysis of the use of alternatives to
culture such as microscopic observation drug susceptibility test
(MODS) [30], as this was not practiced on site, and we found no
good source of costing data. We examined the effect of
reprogramming Xpert so that no resistance result is obtained.
In addition, we conducted a probabilistic sensitivity analysis
(Monte Carlo simulation) to explore the effect of uncertainty across
our model parameters. This analysis randomly sampled each
parameter in our model simultaneously from their probability
distribution (Table 1; Text S1), and repeated this 10,000 times to
generate confidence intervals around our estimates of incremental
cost per DALY averted.
The model and the analyses were constructed using TreeAge
software. Percentage ranges in the text reflect ranges across
countries unless stated otherwise.
The demonstration study was endorsed by national TB pro-
grammes of participating countries and approved by nine governing
institutional review boards (IRBs). The requirement to obtain
individual informed consent was waived. The costing and cost-
effectiveness assessments were outlined in the study protocol reviewed
by the IRBs.
Results
The cost for the Xpert test (including all costs, such as the
cartridge, equipment, salaries) ranges from US$22.63 in India to
US$27.55 in Uganda, at an Xpert cartridge price of US$19.40
(including a 25% mark-up for transportation) and US$17,000 per
four-module instrument (Tables 2 and 3) [2]. This cost falls to as
low as US$14.93 with volume-driven price reductions. As FIND
has negotiated a fixed price for Xpert, the difference in costs
between sites is primarily determined by the intensity of use of the
four-module instrument. Other factors also influence costs, but to
a lesser extent; these include local wage levels and the room space
used. A single sputum smear examination costs between US$1.13
and US$1.63. Unit costs for culture (Lo¨wenstein–Jensen [LJ] or
mycobacteria growth indicator tube [MGIT]) range from
US$13.56 to US$18.95. Unit costs for tests that diagnose MDR-
TB (where relevant for all first-line drugs) range from US$20.23
for LPA only to US$44.88 for MGIT and LPA.
The use of Xpert substantially increases TB case finding in all three
settings; from 72%–85% to 95%–99% of the TB suspect cohort
(Table 4). When Xpert is deployed ‘‘as a replacement of’’ instead of
‘‘in addition to’’ smear microscopy, the number of TB cases detected
is similar—while the number of MDR-TB cases detected increases
substantially. When undiagnosed TB patients are assumed not to
return for diagnosis, TB case detection increases from 62%–76% in
the base case to 86%–94% in the Xpert scenarios.
The diagnostic cost (including the costs of testing all individuals
with suspected TB) per TB case detected is US$28–US$49 for the
base case and increases significantly to US$133–US$146 and
US$137–US$151 when Xpert is used ‘‘in addition to’’ and ‘‘as a
replacement of’’ smear microscopy, respectively, depending on the
setting (Table 4). The resulting change in treatment costs is more
moderate, due to a reduction in the numbers of false positives in
the base case from clinical diagnosis. For example, in India, the
percentage of treatment costs spent on false-positive diagnoses falls
from 22% to 4% when Xpert is used ‘‘as a replacement of’’ smear
microscopy in comparison to the base case.
Cohort Proportions and Diagnostic Parameters India South Africa Uganda Distribution Source
HIV positive, sputum smear-positive 9.67 (8.62,
10.39)
11.03 (9.85,
11.90)
11.92 (10.63,
12.90)
Triangular See Text S1
HIV negative, sputum smear-positive 16.43 (16.02,
16.79)
17.52 (17.05,
17.93)
22.63 (22.13,
23.07)
Triangular See Text S1
The distribution column indicates which probability distribution was specified for each parameter in the Monte Carlo simulations. For triangular distributions the mode,
upper and lower limit are given. All beta distributions have boundaries (0, 1).
SEM, standard error of the mean.
doi:10.1371/journal.pmed.1001120.t001
Table 1. Cont.
Cost-Effectiveness of Xpert MTB/RIF
PLoS Medicine | www.plosmedicine.org 5 November 2011 | Volume 8 | Issue 11 | e1001120
ICERs for each Xpert scenario are presented in Table 5. The
mean ICER for using Xpert ‘‘in addition to’’ smear microscopy
compared to the base case ranges from US$41 to US$110 per
DALY averted depending on the setting. The mean ICER for
using Xpert ‘‘as a replacement of’’ smear microscopy ranges from
US$52 to US$138 per DALY averted. The mean ICER for using
Xpert as ‘‘a replacement of’’ smear microscopy compared to using
Xpert ‘‘in addition to’’ smear microscopy ranges between US$343
and US$650. This higher ICER is due to the fact that the
effectiveness gain from using Xpert as ‘‘replacement of smear
microscopy’’ is derived from additional MDR-TB cases detected,
and the cost-effectiveness of treating MDR-TB is lower than that
for drug-susceptible TB. All the ICERs found are well below the
WTP threshold.
The results of the probabilistic sensitivity analysis (Monte Carlo
simulation) are also shown in Table 5. Aside from the replacement
of smear microscopy in Uganda all estimates remain cost-effective.
Figure 2 provides an illustration of the cost-effectiveness of Xpert
deployed as ‘‘a replacement of’’ smear microscopy in comparison
to the ‘‘in addition to’’ scenario for a range of WTP thresholds.
This graph, known as an acceptability curve, shows that if the
WTP is US$490 in Uganda, there is around a 75% probability
that Xpert as a replacement of smear is cost-effective when
compared to the ‘‘in addition to’’ scenario.
Nearly all of our one- and two-way sensitivity analyses did not
increase the ICER compared to the base case of either Xpert
scenario above the WTP threshold (Table 6). Figure 3 shows
ICER variation when parameters for the suspect population and
the performance of the base case change. Varying the true
proportion of those with TB and MDR-TB in the cohort has little
effect on our results, although Xpert ICERs substantially worsen
when the proportion of smear-positive TB cases becomes 5% or
less (translating into 7%–9% with any type of TB). Varying
assumptions on the performance of the base case alters ICERs
substantially. Increasing the sensitivity of smear examination
reduces the cost-effectiveness of Xpert, but not below the WTP
threshold. If clinical diagnosis has a higher specificity and lower
sensitivity than in our study sites, Xpert ICERs worsen, but also
remain below the WTP threshold. But, if clinical diagnosis has a
lower specificity and higher sensitivity than in our study sites,
ICERs for Xpert substantially improve. Adding chest X-ray for
50% of the individuals with suspected TB tested by Xpert has
limited impact on the cost-effectiveness of Xpert. Adding clinical
diagnosis for all HIV-positive individuals with suspected TB with a
negative Xpert result has no or limited effect in India and South
Africa, but doubles ICERs for Xpert in Uganda (although not
above the WTP threshold). This reflects differences in HIV
prevalence as well as relatively high cost and low specificity of
clinical diagnosis in Uganda owing to more extensive use of X-ray.
Incorporating the cost of culture and increasing the proportion of
TB diagnosis based on the culture result, has a mixed effect. Xpert
remains cost-effective up until the point where 40%–70% of
patients receive a culture-based diagnosis. Above proportions of
50%–90%, the base case becomes more effective. If however,
culture performance is less than 100%, the base case does not
become more effective than the Xpert-based scenarios until nearly
100% of patients receive a culture-based diagnosis (unpublished
data).
Discussion
Our results suggest that Xpert is likely to be more cost-effective
than a base case of smear microscopy and clinical diagnosis of
smear-negative TB. The extent and type of cost-effectiveness gain
from deploying Xpert is dependent on a number of different
setting-specific factors. First and foremost of these factors is the
performance of current TB diagnostic practice. Where the
sensitivity of current practice is low, but specificity high, Xpert
Table 3. Cost of Xpert (current pricing) by input type (2010
US$).
Input Type Costs per Test (2010 US$)
India South Africa Uganda
Overhead 0.18 0.88 0.40
Building space 0.02 0.08 0.12
Equipment 2.84 3.50 7.00
Staff 0.11 1.82 0.24
Reagents and chemicals 19.40 19.40 19.40
Consumables 0.07 0.22 0.38
Total 22.63 25.90 27.55
doi:10.1371/journal.pmed.1001120.t003
Table 2. Cost of diagnostic tests at the study sites (2010 US$).
Diagnostic Test Type of Laboratory Costs per Test (2010 US$)
India South Africa Uganda
AFB Smear (one smear) Peripheral/hospital 1.13 1.58 1.63
Xpert (current pricing) US$19.4 including transport Peripheral/hospital 22.63 25.90 27.55
Xpert (volume.1.5 million/y) US$15.5 including transport Peripheral/hospital 18.73 22.00 23.61
Xpert (volume.3.0 million/y) US$11.7 including transport Peripheral/hospital 14.93 18.20 19.85
Culture (LJ) Reference 13.56 — 15.45
Culture (MGIT) Reference — 15.24 18.95
Culture + DST (LJ) Reference 22.33 — 23.98
Culture + DST (MGIT) Reference — 41.17 44.88
DST (MGIT + LPA) Reference — 33.01 38.82
DST (LPA), on sputum Reference — 20.23 21.84
doi:10.1371/journal.pmed.1001120.t002
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has a substantial impact on effectiveness. Where the sensitivity of
current practice is high, but specificity low, Xpert will lower
treatment costs by reducing the number of false positives. This
latter effect is illustrated by the case of Uganda, where the model
predicts a reduction in the treatment costs of false positives from
US$171,803 to US$14,908, contributing to the overall reduction
in treatment costs.
Other factors that are likely to determine the extent of cost-
effectiveness gain include the proportion of those co-infected with
HIV and the proportion of those with MDR-TB, and the numbers
of true TB cases in the suspect population. However, our results
show that increasing proportions of HIV in the suspect population
will not always reduce the ICER of Xpert (Figure 3). This finding
is counter-intuitive. One would expect the cost-effectiveness of a
diagnostic test that diagnoses smear-negative TB to improve with
increases in HIV prevalence. However, as the proportion of
individuals co-infected with HIV in the suspect population
increases, so the sensitivity of Xpert decreases. Depending on
the relative costs and performance of the base case, this counter-
effect means that the relationship between HIV prevalence and
Xpert’s cost-effectiveness is weaker than anticipated.
Nor can we conclude on the direction of the relationship
between cost-effectiveness gain and the level of prevalence of
MDR-TB in the suspect population at this time. Our model
demonstrates that when transmission effects are excluded, the
ICER of Xpert increases as the MDR-TB prevalence
increases (Figure 3). This result occurs because although the
effectiveness of Xpert increases with a higher MDR-TB
prevalence, the ICER of treating MDR-TB is higher than that
of drug susceptible TB, thus countering the gain from increased
effectiveness.
Unsurprisingly, we also find that higher proportions of TB cases
in the suspect population improve the cost-effectiveness of Xpert.
The cost per TB case detected will also decrease with increases in
TB prevalence. As TB programmes already fund elements of the
base case, cost-effectiveness may therefore be initially improved by
using existing diagnostic tools, such as X-ray and clinical scores, to
screen the TB suspect population prior to Xpert. In the longer run,
however, the expansion of X-ray as a permanent approach for
suspect screening is unlikely to be cost-effective, and further work
examining alternative screening approaches may be required.
Moreover, different approaches are likely to be adopted for
specific suspect populations, most notably those already known to
be HIV infected, those who have already failed treatment, and
those at a high risk of MDR-TB. We therefore recommend that
further work is conducted to explore the impact on cost-
effectiveness of different algorithms when Xpert is applied to
more limited suspect groups.
A number of factors limit our analysis. Firstly, the assumption of
no transmission effects or additional mortality benefit from early
diagnosis is a conservative approach and will underestimate the
cost-effectiveness of Xpert—particularly where the introduction of
Xpert is likely to increase the numbers of drug-resistant patients
who are appropriately and rapidly treated. Likewise, we do not
factor in patient costs. A full societal evaluation would make all
options less cost-effective, but Xpert is likely to fare better than
alternatives, as it requires fewer patient visits. In addition, if Xpert
can achieve earlier diagnosis, substantial reductions in patient costs
prior to treatment may be achieved [31]. The reference standard
for the test performance parameters in our model did not include
culture-negative TB based on response to treatment, because this
diagnostic category will include cases with no TB or extra-
pulmonary TB that cannot be diagnosed by sputum-based tests.
This situation may have lead to overestimation of the sensitivity
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and underestimation of the specificity of Xpert. Owing to lack of
evidence, we only included one repeat visit for false negatives in
our model, to capture those who quickly progress to smear-
positive TB. This number may be insufficient and miss both the
additional costs and effectiveness of further repeated visits. On
the other hand, our assumption that 100% of false negatives still
alive and with TB after 3 mo have a repeat visit may be an
overestimation, thereby inflating ICERs for the Xpert scenarios.
We assumed that a negative Xpert result does not lead to further
TB diagnostic procedures. This assumption may not be true in
practice, in particular not for HIV-infected individuals with
suspected TB [32]. Our sensitivity analyses show that adding
clinical diagnostic procedures for this group can substantially
reduce cost-effectiveness of Xpert when HIV prevalence is high
and X-ray is used extensively. Also because of the lack of data, we
have not included a high MDR-TB, but low HIV-prevalence
setting. This lack of data restricts our ability to generalise findings
to all low- and middle-income settings, particularly the former
Soviet states, where this epidemiological pattern is common in
suspect populations. Finally, our sensitivity analysis demonstrates
that Xpert may not be cost-effective when compared to a base
case in which a high proportion of smear-negative TB cases are
diagnosed by culture. However, this result is based on our
assumption that culture performs at 100% sensitivity and
specificity. In addition, we did not include costs of specimen
transport, increased risk of false-negative cultures or contamina-
tion, reduced sensitivity when only one specimen is cultured, and
possible delay effects on mortality and patient drop out. All these
simplifications will inflate the cost-effectiveness of a base case that
includes culture.
As is standard practice, we determine cost-effectiveness in
comparison to the WHO WTP threshold. Unfortunately,
achieving this threshold does not mean that the resources are
available in low- and middle-income countries, merely that Xpert
should be afforded [33]. In reality, resourcing for tuberculosis
services in low- and middle-income countries is extremely
constrained. Countries may therefore need to prioritise. In terms
of priorities, suspect populations with a high likelihood of TB,
particularly in settings with high HIV and MDR-TB prevalence,
are an obvious choice. However, our findings illustrate that it is
also important to balance these factors with the current
performance of the existing diagnostic pathway. Countries or
areas that have the weakest performance in terms of diagnosing
smear-negative cases may benefit the most, even when they have
relatively low levels of MDR-TB and HIV; although additional
investment may be required to strengthen aspects of the health
system to ensure that Xpert can be implemented successfully.
Funding Xpert may also mean that scarce resources are not made
available to other equally deserving areas. Care must therefore be
exercised to take into account the broader tuberculosis control
and health system needs of any particular setting when funding
Xpert.
Our model is robust given the current evidence and data
available. However, key data in this area—particularly on the
characteristics of TB suspect populations, the feasibility of
implementing Xpert at scale, and the extent to which clinicians
allow diagnostic test results to influence treatment decisions—
remain scarce. Moreover, it is likely that there will be costs
associated with Xpert scale-up that we cannot predict at this point.
Although our model strongly suggests that Xpert will be cost-
effective in a wide variety of settings, Xpert scale-up will
substantially increase TB diagnostic costs. Given this increase,
and the current data paucity, we recommend careful monitoring
and evaluation of initial roll-out before full scale-up. Funding
should be provided for implementation studies, including
pragmatic trials, in a number of countries to accelerate this
process. As we did not assess cost-effectiveness in a setting with
high MDR but low HIV prevalence, we also recommend
additional economic modelling studies before embarking on roll-
out in these settings, taking into consideration operational factors
that may affect outcomes such as patient drop-out and physician
behavior [34]. Finally, although Xpert is a highly promising
technology, there is still room for improvement in TB diagnostics.
Xpert has incomplete sensitivity for smear-negative TB and
rifampicin resistance and does not detect resistance to isoniazid
and other drugs. Other promising tests, such as microscopic
observation drug susceptibility test (MODS) [35], should be
evaluated for their cost-effectiveness, including comparisons with
Table 5. Cost per DALY (US$ 2010).
Country Scenario Total Cost
Total
DALYS
Cost per
DALY
ICER Compared
to Base Case,
Mean
Monte Carlo
Simulation ICER,
Median (2.5, 97.5)
ICER Compared
to in Addition to,
Mean
Monte Carlo
Simulation ICER,
Median (2.5, 97.5)
India Base case 513,698 17,133 30 — — — —
In addition
to smear
664,191 19,887 33 55 54 (40, 70) — —
Replacement
of smear
709,248 20,019 35 68 68 (51, 87) 343 361 (239, 578)
South Africa Base case 1,084,698 15,805 69 — — — —
In addition
to smear
1,594,276 20,420 78 110 109 (88, 133) — —
Replacement
of smear
1,758,467 20,702 85 138 136 (105, 172) 582 594 (353, 956)
Uganda Base case 544,499 22,182 25 — — — —
In addition
to smear
643,172 24,570 26 41 34 (23, 69) — —
Replacement
of smear
670,137 24,611 27 52 37 (0, 73) 650 276 (21895, 2,406)
doi:10.1371/journal.pmed.1001120.t005
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Xpert. Our finding should not discourage investment in other
promising new TB diagnostic technologies, particularly those that
further improve the diagnostic sensitivity and detection of wider
forms of drug resistance and can be implemented at peripheral
health care level at low cost.
Conclusion
Despite the fact that there is considerable concern from policy
makers about the costs and affordability of new diagnostic
technologies in low- and middle-income countries, our results
suggest that Xpert is likely to be a highly cost-effective investment.
If demonstrated test performance is maintained at scale, Xpert
has the potential to substantially increase TB case detection.
Moreover, in the settings modelled, TB treatment costs are not
predicted to substantially increase with the introduction of Xpert;
instead, treatment is likely to be switched from those who do not
benefit from treatment, to those who do. Our results suggest that
funding should be provided to initiate the roll-out of Xpert in low-
and middle-income countries, as a promising means of enabling
access to effective treatment for all those with the disease. We
Figure 2. Cost-effectiveness acceptability curves. ICER ‘‘replacement of smear’’ compared with ‘‘in addition to smear.’’
doi:10.1371/journal.pmed.1001120.g002
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recommend, however, that this roll-out is carefully evaluated to
validate our results before full scale-up—to ensure that Xpert
implementation is done in a way that does not negatively impact
TB programmes, their funding, and the health systems that
support them.
Supporting Information
Text S1 Details of model assumptions, test turnaround times
(Table S[A]), treatment outcome probabilities (Table S[B]),
probabilities of death and spontaneous recovery with false-
negative tuberculosis diagnosis (Table S[C]), and variables used
in the DALY calculations (Table S[D]).
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Editors’ Summary
Background. Tuberculosis (TB) is a bacterial disease that
infects one-third of the world’s population. The disease is
caused by Mycobacterium tuberculosis, a bacterium that most
commonly infects the lungs (known as pulmonary TB) and
is transmitted from person to person when an infected
individual coughs, sneezes, or talks. The symptoms of TB
include chest pain, weight loss, fever, and a persistent cough
that sometimes contains blood. Only 5%–10% of people who
are infected with TB become sick or infectious, but people
with weakened immune systems, such as individuals who are
HIV-positive, are more likely to develop the disease. TB is
estimated to have killed 1.7 million people in 2009 and is
currently the leading cause of death among people infected
with HIV.
Why Was This Study Done? Although TB can be treated
with a six-month course of antibiotics, effectively diagnosing
TB is not always straightforward and drug resistance is
becoming an increasing problem. One of the most common
and simple methods to diagnose TB is a technique called
sputum smear microscopy, which involves examining matter
from the lungs under a microscope for the presence of
TB-causing bacteria. However, despite being cheap and
relatively simple, the test does not always detect active TB
(smear-negative) and cannot determine whether the TB-
causing bacteria are resistant to antibiotics. The World Health
Organization has recently endorsed a new rapid test, called
Xpert MTB/RIF (referred to as Xpert), for the initial diagnosis
of TB. The test uses DNA amplification methods to reliably
and quickly detect TB and whether infecting bacteria are
resistant to the antibiotic rifampicin. The new test is
expensive so there are concerns that the test might not be
cost-effective in low- and middle-income countries.
What Did the Researchers Do and Find? The researchers
used a technique called modeling to simulate the outcome
of 10,000 individuals with suspected TB as they went
through a hypothetical diagnostic and treatment pathway.
The model compared the costs associated with the
introduction of Xpert to a base case for two different
scenarios. In the base case all individuals with suspected TB
had two sputum smear microscopy examinations followed
by clinical diagnosis if they were smear-negative. For the
different scenarios Xpert was either used in addition to the
two sputum smear microscopy examinations (if the patient
was smear-negative) or Xpert was used as a replacement for
sputum smear microscopy for all patients. Different input
parameters, based on country-specific estimates, were
applied so that the model reflected the implementation of
Xpert in India, South Africa, and Uganda.
In the researcher’s model the introduction of Xpert increased
the proportion of TB-infected patients who were correctly
diagnosed with TB in any of the settings. However, the cost
per TB case detected increased by approximately US$100 in
both scenarios. Although the cost of detection increased
significantly, the cost of treatment increased only moderately
because the number of false-positive cases was reduced. For
example, the percentage of treatment costs spent on false-
positive diagnoses in India was predicted to fall from 22%
to 4% when Xpert was used to replace sputum smear
microscopy. The model was used to calculate incremental
cost effectiveness ratios (ICERs—the additional cost of each
disability-adjusted life year [DALY] averted) for the different
scenarios of Xpert implementation in the different settings.
In comparison to the base case, introducing Xpert in addition
to sputum smear microscopy produced ICERs ranging from
US$41 to US$110 per DALY averted, while introducing Xpert
instead of sputum smear microscopy yielded ICERs ranging
from US$52 to US$138 per DALY averted.
What Do These Findings Mean? The findings suggest
that the implementation of Xpert in addition to, or instead
of, sputum smear microscopy will be cost-effective in low-
and middle-income countries. The calculated ICERs are
below the World Health Organization’s ‘‘willingness to pay
threshold’’ for all settings. That is the incremental cost of
each DALY averted by introduction of Xpert is below the
gross domestic product per capita for each country ($1,134
for India, $5,786 South Africa, and $490 for Uganda in 2010).
However, the authors note that achieving ICERs below the
‘‘willingness to pay threshold’’ does not necessarily mean
that countries have the resources to implement the test. The
researchers also note that there are limitations to their study;
additional unknown costs associated with the scale-up of
Xpert and some parameters, such as patient costs, were not
included in the model. Although the model strongly
suggests that Xpert will be cost-effective, the researchers
caution that initial roll-out of Xpert should be carefully
monitored and evaluated before full scale-up.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001120.
N The World Health Organization provides information on all
aspects of tuberculosis, including tuberculosis diagnostics
and the Stop TB Partnership (some information is in several
languages)
N The US Centers for Disease Control and Prevention has
information about tuberculosis, including information on
the diagnosis of tuberculosis disease
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
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